Gopa Iyer

1 month ago | urologytimes.com | Gopa Iyer |Hannah Clarke

In this video, Gopa Iyer, MD, shares the background and preliminary findings from the phase 1/2 SURF301 (NCT05544552) trial of TYRA-200 in advanced/metastatic urothelial carcinoma. Iyer is a genitourinary medical oncologist, an early drug development specialist, and the section head of bladder cancer at Memorial Sloan Kettering Cancer Center in New York, New York. Video Transcript:SURF301 is a phase 1 study of a novel FGFR3 inhibitor, TYRA-300. It's an exciting drug.

2 months ago | urotoday.com | Gopa Iyer

Read the Full Video TranscriptSam Chang: Hi, I'm Sam Chang. I'm a urologist at Vanderbilt University in Nashville, Tennessee. And we have both the pleasure and the honor of having Dr. Gopa Iyer from Memorial Sloan Kettering Cancer Center. Dr. Iyer is an associate clinical attending or member there at MSKCC. And I've had the privilege of knowing him for, gosh, maybe 15 or 20 years. We go way back.

Mar 21, 2023 | urotoday.com | Gopa Iyer

Sam Chang is joined in conversation by Gopa Iyer, discussing an article in European Urology that examines the predictive nature of FGFR3 wild-type versus mutant-type and its impact on patient response to perioperative chemotherapy in urothelial carcinoma. The study sought to evaluate the association between FGFR3 alterations and response to platinum-based chemotherapy, both in the perioperative as well as the metastatic setting.